Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD

Along the obesity pandemic, the prevalence of non-alcoholic fatty liver disease (NAFLD), often regarded as the hepatic manifestation of the metabolic syndrome, increases worldwide representing now the prevalent liver disease in western countries. No pharmacotherapy is approved for the treatment of N...

Descripción completa

Detalles Bibliográficos
Autores principales: Seghieri, Marta, Christensen, Alexander S., Andersen, Andreas, Solini, Anna, Knop, Filip K., Vilsbøll, Tina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6232120/
https://www.ncbi.nlm.nih.gov/pubmed/30459715
http://dx.doi.org/10.3389/fendo.2018.00649

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6232120/
https://www.ncbi.nlm.nih.gov/pubmed/30459715
http://dx.doi.org/10.3389/fendo.2018.00649

Ejemplares similares